中国和印度可以帮助阻止“疫苗民族主义”吗?
印度和中国是占据全球新冠病毒疫苗产能一半以上的重要生产国,中印双方必须做出更多的努力,才能与"新冠病毒疫苗全球实施计划"(COVAX)共享疫苗供应。
Dr. Nina Rawal is Partner and Co-Head of Trill Impact Ventures, Europe's leading impact investing house. She previously headed the life science investment team at Industrifonden, a USD 800m VC fund. Previous experience also includes Boston Consulting Group in Stockholm and New York, and VP Strategy and Ventures at Gambro (Baxter Group). She serves on the boards of Cinclus Pharma and Stockholms Sjukhem, a non-profit hospital organization.
Nina holds a MSc in Biomedicine and a PhD in Molecular Neurobiology, both from the Karolinska Institute with research work done at Columbia University and Hopital la Salpetriere. Recognition for her work includes the selection as a WEF Young Global Leader and a '40 under 40 - European Young Leader.
印度和中国是占据全球新冠病毒疫苗产能一半以上的重要生产国,中印双方必须做出更多的努力,才能与"新冠病毒疫苗全球实施计划"(COVAX)共享疫苗供应。
India and China, produce over half global capacity of COVID-19 vaccines but must improve supply to COVAX – fair distribution is quickest route to recovery.
Lockdowns could have unintended consequences from which poorer nations might not recover. Could countries like Sri Lanka and Malaysia show a better way?